<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744964</url>
  </required_header>
  <id_info>
    <org_study_id>0078-09-RBM</org_study_id>
    <nct_id>NCT01744964</nct_id>
  </id_info>
  <brief_title>Apomorphine Effects on Experimental Pain</brief_title>
  <official_title>Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study were to assess the effects of the dopamine agonist apomorphine on
      experimental pain models in healthy subjects and to explore the possible association between
      these effects and a common polymorphism within the dopamine transporter gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers (n=105) participated in this randomized double-blind, placebo-controlled,
      cross-over trial. Heat pain threshold and intensity, cold pain threshold, and the response to
      tonic cold pain (latency, intensity, and tolerance) were evaluated before and for up to 120
      min after the administration of 1.5 mg apomorphine/placebo. A polymorphism (DAT-1) within the
      dopamine transporter gene (SLC6A3) was investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cold pain tolerance</measure>
    <time_frame>120 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assessment of experimental pain models before and after treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apomorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assessment of experimental pain models before and after treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apomorphine</intervention_name>
    <description>1.5 mg Apomorphine</description>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Apomorphine</arm_group_label>
    <other_name>Active Comparator: Apomorphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - healthy and free from chronic pain of any type did not use any medications other than
        oral contraceptives were able to understand the purpose and instructions of the study.

        Exclusion Criteria:

        - any type of medical or painful condition use of medications or recreational drugs
        pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elon Eisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus, Haifa, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apomorphine</keyword>
  <keyword>dopamine transporter gene</keyword>
  <keyword>SLC6A3</keyword>
  <keyword>cold pressor test</keyword>
  <keyword>tolerance</keyword>
  <keyword>experimental pain</keyword>
  <keyword>dopamine agonist</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

